Novel AI-Driven Cardiac Blood Test Provides Highly Accurate Prediction of One-Year Risk for Heart Attack, Stroke, or Cardiac Death

(Kirkland, Wash., USA) has been issued a patent by the US Patent Office for its highly accurate blood test, HART CVE, for a patient’s one-year risk of heart attack, stroke, or cardiovascular death. The company leveraged its AI-driven HART platform and expertise in cardiac blood tests to develop HART CVE. The company recently announced an international 1,500+ patient study using HART CVE. When the HART CVE test score was divided into low-risk and high-risk categories, the test predicted with 98% accuracy (negative predictive value) that a low-risk patient would not have a heart attack or major cardiac event within one year.

In addition to the HART CVE test for one-year risk of a cardiac event, Prevencio has recently launched a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries. HART CADhs was shown to be more accurate (86% AUC accuracy) than standard-of-care stress tests (52% AUC accuracy). HART CVE and HART CADhs tests are currently available to medical professionals for patient use.

“This AI-powered risk score test provides improved accuracy as compared to clinical risk factors and single protein tests. The test could be particularly useful for patients with suspected or known stable and acute heart disease, for which there are very few prognostic risk models,” said James L. Januzzi, MD, a practicing cardiologist at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School and Principal Investigator in development, validation, and ongoing testing of the HART CVE test. “In addition to leading to more appropriate care of patients, it is well-suited for a role in ‘enriching’ pharmaceutical cardiac clinical trials, which could lead to lower trial costs and reduced time to complete clinical trials.”

Related Links:

Prevencio, Inc.